Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of NPT189 in Healthy Subjects
NCT03879278Phase 1Terminated
- Sponsor
- Proclara Biosciences
- Start
- Mar 2019
- Primary completion
- Jun 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PCS-01 in systemic amyloidosis (3 arms), sponsored by Proclara Biosciences. Primary endpoint: Adverse event assessment. Started Mar 2019; status: terminated.
02
Drugs
PCS-01
03
Conditions
systemic amyloidosis
Beyond the preview
Go deeper on NCT03879278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03879278.